Immune Cell Profiling of IFN-λ Response Shows pDCs Express Highest Level of IFN-λR1 and Are Directly Responsive via the JAK-STAT Pathway

Journal of Interferon and Cytokine Research

Volumn 36, Issue 12, 2016, Pages 671-680

  Kelly, Aoife ^a,f   Robinson, Mark W ^a   Roche, Gerard ^a   Biron, Christine A ^b   O'Farrelly, Cliona ^a,c   Ryan, Elizabeth J ^d,e  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b BROWN UNIVERSITY   (United States)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

dendritic cells; JAK STAT; peripheral blood mononuclear cells; Type III IFNs

Indexed keywords

ALPHA INTERFERON; CD123 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; EUKARYOTIC TRANSLATION INITIATION FACTOR 2 ALPHA KINASE 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERFERON; INTERFERON LAMBDA; INTERFERON LAMBDA 3; INTERFERON LAMBDA RECEPTOR 1; INTERFERON RECEPTOR; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 28A; INTERLEUKIN 29; JANUS KINASE; RIBOSOMAL PROTEIN S15; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; INTERFERON REGULATORY FACTOR; INTERFERON-LAMBDA, HUMAN; LEUKOCYTE ANTIGEN;

ANTIVIRAL ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CELL STIMULATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LEUKOCYTE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; STAINING; TREATMENT RESPONSE; UPREGULATION; DENDRITIC CELL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MONONUCLEAR CELL; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIGENS, CD; ANTIVIRAL AGENTS; B-LYMPHOCYTES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPHENOTYPING; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; INTERFERONS; JANUS KINASES; LEUKOCYTES, MONONUCLEAR; MONOCYTES; PHOSPHORYLATION; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 85003454042     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2015.0169     Document Type: Article

References (38)

1. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z, Haugen H, Klucher K, Paludan SR. 2008. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180(4):2474-2485.
2. Chen H, Sun H, You F, Sun W, Zhou X, Chen L, Yang J, Wang Y, Tang H, Guan Y, Xia W, Gu J, Ishikawa H, Gutman D, Barber G, Qin Z, Jiang Z. 2011. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell 147(2): 436-446.
3. Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, Shankey TV. 2005. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry A 67(1):4-17.
4. de Groen RA, Groothuismink ZM, Liu BS, Boonstra A. 2015. IFN-lambda is able to augment TLR-mediated activation and subsequent function of primary human B cells. J Leukoc Biol 98(4):623-630.
5. Dickensheets H, Sheikh F, Park O, Gao B, Donnelly RP. 2013. Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol 93(3):377-385.
6. Eriksen KW, Sommer VH, Woetmann A, Rasmussen AB, Brender C, Svejgaard A, Skov S, Geisler C, Odum N. 2004. Biphasic effect of interferon (IFN)-alpha: IFN-alpha up- and down-regulates interleukin-4 signaling in human T cells. J Biol Chem 279(1):169-176.
7. Gallagher G, Megjugorac NJ, Yu RY, Eskdale J, Gallagher GE, Siegel R, Tollar E. 2010. The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J Interferon Cytokine Res 30(8):603-615.
8. Gaudieri S, Lucas M, Lucas A, McKinnon E, Albloushi H, Rauch A, di Iulio J, Martino D, Prescott SL, Tulic MK. 2012. Genetic variations in IL28B and allergic disease in children. PLoS One 7(1):e30607.
9. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399-401.
10. Gupta S, Jiang M, Pernis AB. 1999. IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. J Immunol 163(7):3834-3841.
11. Jilg N, Lin W, Hong J, Schaefer EA, Wolski D, Meixong J, Goto K, Brisac C, Chusri P, Fusco DN, Chevaliez S, Luther J, Kumthip K, Urban TJ, Peng LF, Lauer GM, Chung RT. 2014. Kinetic differences in the induction of interferon stimulated genes by interferon-alpha and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 59(4):1250-1261.
12. Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G. 2007a. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun 8(1):13-20.
13. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, Gallagher G. 2007b. Human interferon lambda-1 (IFNlambda1/ IL-29) modulates the Th1/Th2 response. Genes Immun 8(3):254-261.
14. Kelly A, Fahey R, Fletcher JM, Keogh C, Carroll AG, Siddachari R, Geoghegan J, Hegarty JE, Ryan EJ, O'Farrelly C. 2014. CD141(+) myeloid dendritic cells are enriched in healthy human liver. J Hepatol 60(1):135-142.
15. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, Kotenko SV, Sideras P, Lehr HA, Tepe M, Klucher KM, Doyle SE, Neurath MF, Finotto S, Andreakos E. 2011. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 3(6):348-361.
16. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69-77.
17. Lauterbach H, Bathke B, Gilles S, Traidl-Hoffmann C, Luber CA, Fejer G, Freudenberg MA, Davey GM, Vremec D, Kallies A, Wu L, Shortman K, Chaplin P, Suter M, O'Keeffe M, Hochrein H. 2010. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med 207(12):2703-2717.
18. Liu BS, Janssen HL, Boonstra A. 2011. IL-29 and IFNa differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNg receptor expression. Blood 117(8): 2385-2395.
19. Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM. 2007. Interferon: cellular executioner or white knight? Curr Med Chem 14(12):1279-1289.
20. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM. 2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131(6):1887-1898.
21. Megjugorac NJ, Gallagher GE, Gallagher G. 2009. Modulation of human plasmacytoid DC function by IFN-lambda1 (IL- 29). J Leukoc Biol 86(6):1359-1363.
22. Mennechet FJ, Uze G. 2006. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3- expressing suppressor T cells. Blood 107(11):4417-4423.
23. Miyagi T, Lee SH, Biron CA. 2010. Intracellular staining for analysis of the expression and phosphorylation of signal transducers and activators of transcription (STATs) in NK cells. Methods Mol Biol 612:159-175.
24. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, Tough DF. 2002. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99(9):3263-3271.
25. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, Staeheli P. 2008. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 4(9):e1000151.
26. Pott J, Mahlakõiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, Staeheli P, Hornef MW. 2011. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 108(19):7944-7949.
27. Robek MD, Boyd BS, Chisari FV. 2005. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79(6): 3851-3854.
28. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. 2003. IL-28, IL-29 and their class II cytokine receptor IL- 28R. Nat Immunol 4(1):63-68.
29. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFNlambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4(3):e1000017.
30. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41(10): 1100-1104.
31. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41(10): 1105-1109.
32. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265):798-801.
33. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, Relman DA. 2010. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 5(3):e9753.
34. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K. 2009. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 10(8):702-714.
35. Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, Lewis-Antes A, Amrute SB, Garrigues U, Doyle S, Donnelly RP, Kotenko SV, Fitzgerald-Bocarsly P. 2012. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol 189(6):2735-2745.
36. Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, Goto K, Peng LF, Chen WC, Chung RT. 2011. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 55(2):289-298.
37. Zhang S, Kodys K, Li K, Szabo G. 2013. Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. Gastroenterology 144(2):414-425 e7.
38. Zhu H, Butera M, Nelson DR, Liu C. 2005. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J 2:80.